Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | KCNK3 | O14649 | 6/20 | 0.60 |
| ▸ | KCNK9 | Q9NPC2 | 6/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | GRM5 | P41594 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765642 | 0.91 | MAPT (0.69) | MAPTCYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL3774150 | 0.90 | MAPT (0.57) | MAPTKCNK3KCNK9CYP1A2CYP3A4 | |
| SCHEMBL3771262 | 0.87 | MAPT (0.71) | MAPTCYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL3774815 | 0.86 | TP53 (0.58) | MAPTKCNK3KCNK9PKMPPARG | |
| SCHEMBL3774731 | 0.84 | MAPT (0.54) | MAPTHPGDKMT2A | |
| SCHEMBL3771748 | 0.84 | PTGES (0.69) | MAPTKCNK3KCNK9CYP1A2CYP3A4 | |
| SCHEMBL3771548 | 0.84 | BCHE (0.68) | MAPTHPGDKMT2A | |
| SCHEMBL3779966 | 0.84 | MAPT (0.54) | MAPTPPARGHPGDKMT2A | |
| SCHEMBL23080128 | 0.83 | BCHE (0.75) | MAPT | |
| SCHEMBL3770493 | 0.81 | KCNK3 (0.60) | MAPTKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | claimed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | IL1B, LITAF, CYP11B1 | MAPT 1426/4885KCNK3 1692/4885KCNK9 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.